Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884571 | 0.89 | NR1H2 (0.52) | NR1H2NR1H3LMNAMAPT | |
| SCHEMBL15727387 | 0.84 | NR1H2 (0.50) | NR1H2NR1H3LMNAMAPT | |
| SCHEMBL5635574 | 0.82 | NR1H2 (0.67) | NR1H2NR1H3 | |
| SCHEMBL13053317 | 0.79 | PTGS2 (0.47) | MEN1LMNATP53MAPTCACNA1B | |
| SCHEMBL13053318 | 0.76 | NR1H2 (0.45) | NR1H2NR1H3MEN1MAPTKMT2A | |
| SCHEMBL23320505 | 0.75 | CYP19A1 (0.59) | NR1H2NR1H3 | |
| SCHEMBL12996827 | 0.74 | NR1H2 (0.43) | NR1H2NR1H3MEN1MAPTKMT2A | |
| SCHEMBL2884790 | 0.73 | SIGMAR1 (0.45) | MEN1LMNATP53MAPTCACNA1B | |
| SCHEMBL3033204 | 0.73 | NOD2 (0.51) | MEN1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17220690 | 0.73 | NR1H2 (0.62) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | NR1H2 96/4885NR1H3 60/4885MEN1 4800/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NR1H2 96/4885NR1H3 60/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.